TMEM106A Antibody | 6781

TMEM106A Antibody | 6781 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: TMEM106A antibody was raised against a 14 amino acid synthetic peptide near the amino terminus of human TMEM106A.
The immunogen is located within the first 50 amino acids of TMEM106A.

Research Area: Neuroscience

Tested Application: E, WB, IHC-P, IF

Application: TMEM106A antibody can be used for detection of TMEM106A by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 5 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1288 - A20 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: TMEM106A Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TMEM106A Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TMEM106A antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: TMEM106A Antibody: Transmembrane protein 106A

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: TMEM106A Antibody: Transmembrane protein 106A (TMEM106A) is a single-pass transmembrane protein that is closely related to TMEM106B, a protein that is thought to be a novel risk factor for frontotemporal lobar degeneration (FTLD) , a group of clinically, pathologically and genetically heterogeneous disorders associated with atrophy in the frontal lobe and temporal lobe of the brain. The actual roles of TMEM106A and TMEM106B are still undetermined; however, as TMEM106B is involved in FTLD, it is possible that TMEM106A may also be a risk factor for FTLD.